Eli Lilly’s shares up as oral GLP-1RA scores in first Phase III trial
Eli Lilly’s Phase III trial with its oral weight loss pill, orforglipron, has met its primary endpoint, reducing A1C levels…
Metabolic Disorders
-
-
The GLP-1 drug shortage is over. What’s next for the compounders?
“I am taking compounded semaglutide that I ordered online, but I don’t know how long I will have access to…
-
Pfizer drops obesity pill development after liver injury report
Pfizer has terminated the development of its oral obesity candidate danuglipron after a patient on a clinical trial with the…
-
Obesity drugs won’t be covered by Medicare under 2026 CMS policy
The US Centers for Medicare & Medicaid Services (CMS) confirmed that it will not proceed with a Biden administration proposal…
-
Novo Nordisk earmarks $2bn for Chinese “triple G” weight loss shot
Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth…
-
Opko and Entera focus on oral care for obesity and metabolic disorders
Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral…
-
Vivani treats first patient with long-lasting drug implant for weight loss
A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the…
-
Novo Nordisk cuts Wegovy price through new direct-to-patient online pharmacy
Novo Nordisk is introducing a direct-to-patient delivery option for its flagship weight loss drug Wegovy (semaglutide), slashing the price of…
-
Inborn errors of metabolism elicit unique challenges for therapy development
In recent years, major progress has been made in the development of gene therapies for rare diseases. However, research for…
-
Why pharma is still far from a treatment for galactosemia
Nearly three months after an experimental treatment for classic galactosemia was rejected by the US Food and Drug Administration (FDA),…
